Agilent Technologies, Inc
Agilent Technologies, Inc. designs and sells laboratory instruments and related consumables, software, and services used to analyze biological and chemical samples across research, diagnostics, and applied testing labs. The company is organized around three reportable segments: Life Sciences and Diagnostics Markets (including liquid chromatography and LC/MS platforms), Agilent CrossLab (services, consumables, lab automation, and informatics tied to the installed base), and Applied Markets (including gas chromatography/GCMS, spectroscopy, vacuum, and remarketed instruments). Its business model blends capital equipment sales with recurring revenue from service contracts, repair/compliance services, and consumables that support day-to-day lab operations. Agilent also refurbishes and resells certified pre-owned instruments to serve value-oriented customers and broaden access to its installed base.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLC/LCMS platforms and related solutions used in pharma, biopharma, research and clinical/diagnostics workflows.
Recurring services, consumables, lab automation, and software/informatics supporting the installed base.
GC/GCMS, spectroscopy, vacuum and remarketed instruments used in environmental, food, chemicals and forensics testing.
Products
Reported · share of revenue- Non Instrumentationand Other65.1 %
- Instrumentation34.9 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Agilent sells primarily to laboratories that need regulated, high-uptime analytical workflows, spanning pharmaceutical and biopharmaceutical companies, life science research organizations, and clinical/diagnostics labs. It also serves applied testing end markets such as environmental and forensics, food testing, and chemicals and advanced materials, where customers value method performance, reliability, and compliance documentation. The company uses a multi-channel go-to-market model combining direct sales for large strategic accounts with distributors, resellers, e-commerce, and manufacturers' representatives to broaden coverage. A meaningful portion of demand is tied to customers’ capital expenditure cycles for instruments, while CrossLab’s repair/maintenance services and consumables provide more recurring, installed-base-driven purchasing behavior.
Buy LC/LCMS and other analytical platforms plus service contracts and consumables to support regulated QC and R&D workflows.
Purchase instruments, software/informatics and consumables for discovery and analytical characterization across lab workflows.
Adopt validated analytical solutions and ongoing service to maintain uptime and compliance in clinical/diagnostic settings.
Use GC/GCMS, spectroscopy and related consumables/services for routine, standards-driven testing and reporting.
Buy applied-market instruments and recurring consumables/services to support materials characterization and process analytics.
Strategy
Agilent’s current direction emphasizes a market-focused structure built around three segments, aligning product platforms and customer workflows while centralizing recurring offerings (services, consumables, automation, and informatics) within CrossLab. The company is investing in capacity expansion for nucleic acid-based therapeutics manufacturing in Frederick, Colorado, indicating a push to support growth areas tied to advanced therapeutics supply chains. CrossLab’s strategy prioritizes growing the installed-base monetization through repair, compliance, and maintenance services and by improving customer experience via digital and remote capabilities. Across segments, the company aims to compete on instrument performance and reliability while using global channel coverage and applications expertise to win and retain accounts.
Adds capacity in a growth area and supports customers' advanced therapeutics needs.
Services and consumables are mostly recurring and less cyclical than instruments, supporting resilience.
Enhances customer experience and service quality while supporting efficient scaling across regions.
Geography
Q2/2026Agilent operates globally and sells across the Americas, Europe, and Asia Pacific, with demand influenced by regional research funding, industrial activity, and customer capital spending. The company’s Applied Markets manufacturing footprint includes a U.S. facility in Delaware and international manufacturing in Australia, China, Italy, Malaysia, and Singapore, supporting proximity to customers and supply chain resilience. Management commentary highlights that CrossLab is diversified across regions, which helps hedge localized weakness, but results remain exposed to foreign currency movements. Regional performance can differ by end market mix (e.g., installation and automation softness versus steady repair/maintenance and consumables demand).
Share of the revenue the company reports by geography.
Risks
Demand for Agilent’s instruments is sensitive to macroeconomic conditions and customers’ capital expenditure cycles, which can lengthen sales cycles, increase cancellations, and create price pressure. The company also faces inventory risks (excess and obsolescence) when end-market demand slows or product mix shifts, particularly for configurable instrument platforms. Acquisition execution is a meaningful company-specific risk: integrating acquired businesses can increase systems complexity, raise compliance burdens, and delay expected synergies or margin targets. Like peers in analytical instruments, Agilent operates in intensely competitive markets where performance, reliability, applications support, and price can shift share and compress margins, while foreign currency movements can distort reported growth across regions.
- General economic conditions may adversely affect operating resultsImpact: HighLikelihood: Medium
Slower growth, higher rates and inflation can reduce demand, extend sales cycles, increase cancellations and price pressure, and raise inventory and impairment risks.
Exposure: Global end markets; particularly instrument capital spending
- End-market declines or slower-than-expected growthImpact: HighLikelihood: Medium
If pharma, chemicals/materials or other served markets weaken, instrument demand and related software/installation can fall, pressuring results.
- Acquisition integration and synergy realization riskImpact: MediumLikelihood: Medium
Integrating different cultures, systems and controls can be costly and time-consuming; synergies may be delayed or not achieved, impacting margins and reporting obligations.
Accounting
Judgemental itemsBundled arrangements require allocation and timing judgments that affect revenue and margin by period.
Impact: Can shift revenue between quarters and between product vs service lines
Configurable instruments and stocked products require reserves for obsolescence when demand or technology changes.
Impact: Affects gross margin via write-downs and reserve adjustments
Valuation and impairment testing depend on assumptions about future cash flows and discount rates, especially post-acquisition.
Impact: Potential non-cash impairment charges and amortization profile
Discount rates and return assumptions can materially change pension/benefit expense and obligations.
Impact: Impacts operating expenses and balance sheet liabilities
Tax accounting involves estimates and judgments that can change with audits, law changes, and geographic profit mix.
Impact: Affects effective tax rate and tax-related balance sheet accounts
Similar listed companies
Publicly listed companies with a comparable business focus.
Abbott Laboratories
ABT · Pharmaceutical Preparations
Abbott Laboratories is a U.S.-based healthcare company that discovers, develops, manufactures, and sells a diversified portfolio spanning medical devices,…
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
Qiagen N.V
QGEN · Biological Products, (No Diagnostic Substances)
Ecolab Inc
ECL · Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics
Ecolab makes water treatment, cleaning, sanitizing, and infection-prevention solutions used by industrial, food, healthcare, hospitality, and life sciences customers.
Bionano Genomics, Inc.
BNGO · Laboratory Analytical Instruments
AgEagle Aerial Systems Inc.
UAVS · Aircraft
Last updated: 24/09/2026